A trial fibrillation (AF) is the most common arrhythmia in clinical practice, and its occurrence increases with age. It is associated with increased cardiovascular morbidity and mortality and adversely affects the quality of life. [1] [2] [3] Many randomized clinical trials have examined whether reestablishment and maintenance of sinus rhythm or control of heart rate alone is more effective in the management of AF. However, clinical trials have not yet shown that rhythm control is any better than rate control in decreasing the mortality and morbidity rates of patients with AF. 4, 5 One possible explanation for the ineffectiveness of rhythm control is that the proarrhythmic risk and toxic effects associated with currently available antiarrhythmic drugs adversely affect outcomes. Innovative approaches have been applied to discover an ideal antiarrhythmic drug that can effectively and safely terminate and prevent AF recurrence. An antiarrhythmic drug with selective affinity for the ion channels that are specifically involved in atrial repolarization would be an ideal candidate. 6, 7 
Clinical Perspective on p 102
Considerable attention has recently focused on acetylcholine (ACh)-activated K ϩ (K ACh ) channels that are important for atrial, but not ventricular repolarization and in AF susceptibility. 8, 9 Atrial tachypacing in dogs produces electric remodeling in which the density of the ACh-activated K ϩ current (I K,ACh ) in atrial cells increases, even in the absence of a muscarinic agonist. 10 In addition, I K,ACh is constitutively active in atrial cardiomyocytes from patients with long-term AF. 11 Paroxysmal AF occurring at night, at rest, and/or after consuming meals or alcohol is caused at least partly by K ACh channel activation. 12 However, the contribution of K ACh channel activation to the development and maintenance of AF in patients remains unresolved because a highly selective K ACh channel blocker is not clinically available. Hence, we synthesized the benzopyrane derivative NTC-801 for application as a clinically oriented specific K ACh channel blocker. We show that NTC-801 is a highly selective K ACh channel blocker that effectively treated experimental AF in vitro and in vivo.
Methods
All experiments were performed under the regulations of the Animal Research Committee of Chiba University Graduate School of Medicine or those of the Animal Care and Use Committee of Teijin Institute for Bio-Medical Research.
Effects of NTC-801 on I K,ACh in Guinea Pig Atrial Cells
Whole-cell membrane currents were recorded from single atrial/ventricular cells of the guinea pig heart isolated by enzymatic dissociation, 13 using the patch-clamp method. 14 Detailed methods for atrial cell isolation and patch-clamp are described in the online-only Data Supplement.
Effects of NTC-801 on GIRK1/4 and GIRK1/2 Channels Expressed in Xenopus Oocytes
Oocytes were surgically removed from Xenopus laevis under anesthesia in iced water. Stage V and VI oocytes were injected with 5 ng each of GIRK1 and GIRK4 or GIRK1 and GIRK2 cRNA. Membrane currents were then recorded from the oocytes using the conventional 2-microelectrode voltage-clamp technique. Detailed methods are described in the online-only Data Supplement.
Effects of NTC-801 on 9 Cardiac Ionic Currents
Using human embryonic kidney (HEK) cell lines, Chinese hamster ovary (CHO) cell lines that expressed 1 of the human channels, or isolated ventricular myocytes of guinea pig or rat, effects of NTC-801 on 9 ionic currents of heart cells (I Na , I CaL , I to , I Kur , I Kr , I Ks , I Kl , I KATP , and I f ) were examined by the whole-cell patch-clamp technique. Detailed methods are described in the online-only Data Supplement.
Effects of NTC-801 on Action Potential in Guinea Pig Atrial/Ventricular Cells
Action potentials were recorded in the current clamp mode of patch-clamp in single atrial/ventricular cells isolated from guinea pig hearts. 13 Detailed methods are described in the online-only Data Supplement.
Effects of NTC-801 on Vagal Nerve Stimulation-Induced AF in Dogs
Sixty-two male mongrel dogs weighing 19 to 25 kg were used. Vagal nerve stimulation (VNS)-induced AF models were prepared according to the procedure described previously. 15 Under bilateral VNS, AF was induced by burst atrial stimulation with 4-fold diastolic threshold current. The incidence of AF termination within 15 minutes after the start of NTC-801 (0.3, 1, and 3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) or vehicle (saline) infusion was evaluated. Blood samples were collected immediately after AF termination to measure plasma concentration of NTC-801. Detailed methods are described in the online-only Data Supplement.
Effects of NTC-801 on Atrial and Ventricular Effective Refractory Period and Intra-Atrial Conduction Time Under VNS
Twenty-six female beagle dogs weighing 10 to 12 kg were used. The surgical procedure was essentially the same as that of VNS-induced AF.
Under bilateral VNS, effective refractory period (ERP) was determined using train 10 basic (S1) stimuli followed by a premature (S2) stimulus at a basic cycle length of 300 ms. The ERP was defined as the longest S1-S2 interval failing a propagated response. The conduction time from the low right atrium to the atrial appendix was also determined. The ERP and conduction time were measured before and after NTC-801 (0.3, 1, and 3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) or vehicle (saline) infusion for 15 minutes. The change of ERP before and after the infusion was analyzed. Detailed methods are described in the online-only Data Supplement.
Effects of NTC-801 on Aconitine-Induced AF in Dogs
Sixteen male beagle dogs weighing 9 to 13 kg were used. Aconitineinduced AF models were prepared according to the procedure described previously. 15 AF was induced by a topical application of aconitine (0.1 mg/body) on the right appendage. NTC-801 (0.01, 0.03, and 0.1 mg/kg) or vehicle (10% DMSO-PEG200) was intravenously administered as a bolus injection and then the incidence of AF termination was evaluated within 10 minutes. Detailed methods are described in the online-only Data Supplement.
Effects of NTC-801 on AF Inducibility and Atrial ERP in a Rapid Atrial Pacing Model in Dogs
Twenty-five male mongrel dogs weighing 17 to 25 kg were used. Rapid atrial pacing (RAP)-induced AF models were prepared according to the procedure described previously. 16 After 3 to 4 weeks of RAP (about 400 bpm), AF was induced 10 times by a burst of atrial stimulation at a voltage of 2-fold diastolic threshold. The number of AF inductions was evaluated before and after infusion for 15 minutes with NTC-801 (3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) or vehicle (saline). Atrial ERP with basic cycle lengths of 200, 250, and 300 ms was also measured. Detailed methods are described in the online-only Data Supplement.
Blood Pressure, Heart Rate, ECG Parameters, and Arrhythmia Assessment in Conscious Dogs
These protocols are provided in the online-only Data Supplement.
Drugs
The following drugs were used: NTC-801 (substituted 4-(aralkylamino)-2,2-dimethyl-3,4-dihydro-2H-benzopyran-3-ol, Nissan Chemical Industries, Ltd, Tokyo, Japan), carbachol chloride (Tokyo Chemical Industry Co, Ltd, Tokyo, Japan), tertiapin (Peptide Institute, Inc, Osaka, Japan), atenolol (Wako Pure Chemical Industries, Ltd, Osaka, Japan), and atropine sulfate monohydrate and aconitine (Sigma Chemical Co, Ltd, St Louis, MO). The compositions of the various buffer solutions and pipette solutions are described in the online-only Data Supplement.
Statistics
All data are expressed as meanϮSEM, and nonparametric tests were used throughout the study except for the incidence of AF termination. For 2-group comparisons, the Wilcoxon test or Wilcoxon signed-rank test was used. For multiple comparisons, the Kruskal-Wallis test followed by a nonparametric-type Dunnett (joint ranking) test was used to compare each dose group versus a vehicle-treated group. For evaluation of the differences in the incidence of AF, the Fisher exact test was used. All data were statistically analyzed using SAS software Windows version, Release 8.2 (SAS Institute Inc, Cary, NC). Differences with a probability value of Ͻ0.05 were considered significant. The concentration-response data were fitted, and IC 50 values were obtained using GraphPad PRISM software version 4.01 (GraphPad, La Jolla, CA).
Results

Effects of NTC-801 on I K,ACh in Guinea Pig Atrial Cells
NTC-801 concentration-dependently inhibited carbacholinduced I K,ACh in isolated guinea pig atrial cells ( Figure 1A , 1B, and 1G). Because adenosine can also induce I K,ACh through activating pertussis toxin-sensitive GTP-binding protein in atrial cells, 17 we evaluated the effects of NTC-801 on adenosine-induced I K,ACh . NTC-801 also inhibited the adenosine-induced current to the same extent as it inhibited the carbachol-induced current ( Figure 1C , 1D, and 1G). We then examined the effects of NTC-801 on I K,ACh induced by intracellular loading with the nonhydrolysable GTP analog GTP␥S. NTC-801 also concentration-dependently inhibited the current induced by GTP␥S ( Figure 1E , 1F, and 1G), and the concentration-response curve was superimposable on those of carbachol-and adenosine-induced I K,ACh . The IC 50 values of NTC-801 for the inhibition of carbachol-, adenosine-, and GTP␥S-induced currents were 5.7, 6.2, and 5.7 nmol/L, respectively ( Figure 1G ). NTC-801 inhibited I K,ACh with equal potency irrespective of the activation method.
Effects of NTC-801 on GIRK1/4 and GIRK1/2 Channels Expressed in Xenopus Oocytes
We examined the effects of NTC-801 on human K ACh channels and clarified channel selectivity among GIRK subtypes by comparing the effects of NTC-801 with those of tertiapin on GIRK1/4 and GIRK1/2 channel currents in the Xenopus oocyte expression system. NTC-801 concentrationdependently inhibited the GIRK1/4 current with an IC 50 of 0.70 nmol/L (Figure 2A , 2B, 2C, and Figure 3A ). Tertiapin likewise inhibited the GIRK1/4 current with an IC 50 of 0.41 nmol/L ( Figure 2G , 2H, 2I, and 3B). NTC-801 inhibited the GIRK1/2 current less potently with an IC 50 of 24 nmol/L ( Figure 2D , 2E, 2F, and 3A), whereas the potency of tertiapin inhibition (IC 50 ϭ0.45 nmol/L) was similar to that on the GIRK1/4 current ( Figure 2J , 2K, 2L, and 3B). Thus, NTC-801 inhibition was 34-fold more selective for the GIRK1/4 than the GIRK1/2 current, whereas tertiapin inhibition was almost equivalent between the two.
Effects of NTC-801 on 9 Ionic Currents of Heart Cells
NTC-801 inhibited I Na , I to , and I KATP with IC 50 values of 8.3, 11.6, and 7.8 mol/L, respectively, and all the other ionic currents Ͻ50% with IC 50 values of Ͼ30 mol/L (Table and online-only Data Supplement Figure 1 ). Thus, the IC 50 ratios for all other currents to that of I K,ACh were Ͼ1000-fold.
Effects of NTC-801 on Action Potentials in Guinea Pig Atrial/Ventricular Cells
We examined the effects of NTC-801 on atrial and ventricular action potentials as well as on carbachol-or adenosineinduced action potential shortening in atrial cells. Figure 4A through 4F shows that NTC-801 at 100 nmol/L did not affect action potential duration (APD 90 ) in atrial cells in the absence of agonists ( Figure 4A and 4D) and concentrationdependently reversed the action potential shortening induced by 1 mol/L of carbachol or 10 mol/L of adenosine ( Figure  4B, 4C, 4E, and 4F) . Figure 4G and 4H shows that NTC-801 at 100 nmol/L did not affect APD 90 in ventricular cells. In addition, NTC-801 up to 30 mol/L did not affect on dV/dt max or action potential duration in guinea pig papillary muscles (online-only Data Supplement Table 1 ). NTC-801 did not affect resting membrane potentials in atrial and ventricular cells or in papillary muscles (online-only Data Supplement Table 1 ).
Effects of NTC-801 on VNS-and Aconitine-Induced AF in Dogs
We evaluated the effects of NTC-801 on AF induced by VNS and aconitine. NTC-801 (0.3, 1, and 3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) dose-dependently converted AF to sinus rhythm in the VNSinduced AF model ( Figure 5A and 5C ). The highest dose of NTC-801 restored sinus rhythm in all of 8 dogs, and the effect was statistically significant (Pϭ0.0014) compared with the vehicle-treated group (1 of 8 dogs). The mean plasma concentration at the time of AF termination by NTC-801 at 3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 was about 50 nmol/L. NTC-801 (0.01, 0.03, and 0.1 mg/kg) also dosedependently converted AF to sinus rhythm in the aconitineinduced AF model ( Figure 5B and 5D ). The rates of AF termination by NTC-801 at 0.01, 0.03, and 0.1 mg/kg were 1, 4 (Pϭ0.014), and 4 (Pϭ0.014), respectively, in 4 dogs, whereas that of vehicle was 0 in 4 dogs.
Effects of NTC-801 on AF Inducibility and Atrial ERP in Canine RAP Model
We examined the antiarrhythmic effects of NTC-801 on electrical remodeling-induced AF in the RAP model. Rapid atrial pacing for 3 to 4 weeks increased AF inducibility and decreased ERP in this model ( Figure 6C and 6D ), suggesting the development of electrical remodeling. The AF inducibility before and after NTC-801 administration was, respectively, 95% and 27%, and that of the vehicle-treated group was 83% at both points ( Figure 6A ). NTC-801 (3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) significantly (Pϭ0.0313) decreased AF inducibility in the RAP-induced AF model, compared with that before treatment. NTC-801 also significantly prolonged atrial ERP at basic cycle lengths of 300, 250, and 200 ms by 38.7Ϯ7.9, 38.0Ϯ7.4, and 35.7Ϯ7.1 ms, respectively (basic cycle lengths of 300, 250, and 200 ms; Pϭ0.0038, 0.0038, and 0.0037, respectively; Figure 6B ).
Effects of NTC-801 on Atrial and Ventricular ERP and Intra-Atrial Conduction Time Under VNS
We evaluated the effects of NTC-801 on atrial and ventricular ERP and on intra-atrial conduction time in anesthetized dogs under VNS to determine the mechanism of its anti-AF properties. NTC-801 (0.3, 1, and 3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) dose-dependently prolonged atrial ERP by 10.0Ϯ3.8, 21.3Ϯ3.3, and 30.0Ϯ2.6 ms, respectively, but it did not affect ventricular ERP (Figure 7A and 7B) . Atrial ERP was significantly prolonged under VNS at doses of 1 g ⅐ kg Ϫ1 ⅐ min Ϫ1 (Pϭ0.0204) and 3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 (Pϭ0.0006). The intra-atrial conduction time after NTC-801 administration did not change in any group (data not shown).
Effects of NTC-801 on ECG Parameters in Conscious Dogs
We recorded ECG traces from conscious dogs. Oral administration of NTC-801 (0.1, 1, and 3 mg/kg) did not appreciably affect ECG parameters including QT interval (online-only Data Supplement Figure 3 and online-only Data Supplement Table 2 ).
Discussion
Main Findings
NTC-801 potently inhibited carbachol-induced I K,ACh in guinea pig atrial cells and the GIRK1/4 current in Xenopus oocytes expressing human GIRK1/4 channels. The inhibitory activity of NTC-801 on I K,ACh and the GIRK1/4 current was essentially equivalent to that of tertiapin. NTC-801 also selectively inhibited I K,ACh over other cardiomyocyte currents (I Na , I CaL , I to , I Kur , I Kr , I Ks , I Kl , I KATP , and I f ), with a margin of Ͼ1000-fold. To the best of our knowledge, this is the first synthetic compound to selectively inhibit I K,ACh . These selectivity data are consistent with the findings that NTC-801 hardly affected I Kr and I Ks in guinea pig atrial cells as well as dV/dt max and APD 90 in guinea pig papillary muscle (onlineonly Data Supplement Figure 2 and online-only Data Supplement Table 1 ). We also confirmed that NTC-801 did not affect the QRS and QTc in a conscious dog (online-only Data Supplement Table 2 ), which reflected the outcomes in vitro.
NTC-801 similarly inhibited I K,ACh induced by carbachol, adenosine, and GTP␥S in guinea pig atrial cells. The electro- physiological experiments using guinea pig atrial cells showed that NTC-801 also reversed the action potential shortening induced by carbachol or adenosine within a similar concentration-response range. These results indicate that the site of action by this compound is the K ACh channel itself and/or G-protein. This concept is supported by the finding that NTC-801 at 10 mol/L did not bind to M 2 or A 1 receptors in pharmacological profiling assays (online-only Data Supplement). Furthermore, the effects of NTC-801 on GIRK1/4 and GIRK1/2 currents differed in Xenopus oocytes. Because the GIRK overexpression systems were essentially identical between the GIRK1/4 and GIRK1/2 experiments, the effects would have been similar had NTC-801 acted on G-protein. Thus, NTC-801 probably acts directly on GIRK1/4 channels rather than on G-protein. Tertiapin inhibited both GIRK currents with equivalent potency, whereas NTC-801 inhibited GIRK1/4 current 34-fold more potently than the GIRK1/2 current. This GIRK channel selectivity indicates that NTC-801 should have high therapeutic value as an antiarrhythmic drug because GIRK1/2 channels are mainly expressed in the central nervous system. 18, 19 Hence, NTC-801 at therapeutic concentrations is less likely to exert neurological disturbances such as seizures that are mediated by GIRK1/2 current inhibition in the central nervous system. 20 We investigated the antiarrhythmic potential of a selective I K,ACh blockade induced by NTC-801 in vivo using VNS-and aconitine-induced models as well as the RAP-induced model that simulates AF associated with electrical remodeling. Our findings in the VNS-induced model are consistent with a previous report indicating that a selective I K,ACh blockade produces AF termination and atrial-selective ERP prolongation without affecting ventricular ERP or intra-atrial conduction time under VNS. 21 These results demonstrated the crucial concept of the "atrial-selectivity" of I K,ACh blocker.
We generated an ectopic automaticity-induced AF model using aconitine. Whereas class I antiarrhythmic drugs terminate AF in this model, the present study demonstrated that a selective blocker of I K,ACh can also terminate AF. These results are consistent with the finding of a previous report showing the effectiveness of an antiarrhythmic drug with 
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I K,ACh -blocking action against aconitine-induced AF. 21 Aconitine is considered to inhibit Na ϩ channel inactivation, 22 and resultant intracellular Na ϩ accumulation might increase K ACh channel activity. 23, 24 Hence, the inhibitory effects of NTC-801 on I K,ACh , activated by intracellular Na ϩ accumulation due to aconitine, might contribute to the AF termination. It is commonly assumed that AF induced by K ACh channel activation resulting from muscarinic stimulation is an exclusive model of reentry, whereas aconitine-induced AF represents a model of atrial ectopy/automaticity. However, the results of this study that aconitine-induced AF can be inhibited by a highly-selective K ACh channel blocker clearly indicate that K ACh channel activation is important for atrial arrhythmias that are maintained by both reentry and ectopic mechanisms. A constitutively active (independent of vagal influence) form of K ACh channels has been identified in atrial cardio-myocytes from patients with chronic AF 11 and dog atrial tissues after atrial tachypacing. 10 Rapid atrial pacing causes electrical remodeling in the atrium, generates an arrhythmogenic substrate, and induces AF with a burst of atrial stimulation. 25, 26 Tertiapin suppresses AF in atrial preparations after atrial tachypacing, 10 but whether a selective I K,ACh blockade can result in antiarrhythmic effects in vivo has not been determined. We evaluated the effects of NTC-801 on AF inducibility in the RAP-induced AF model to address this issue. NTC-801 significantly decreased AF inducibility with atrial ERP prolongation, irrespective of stimulation frequency. This is the first report to show that a selective I K,ACh blocker can exert antiarrhythmic effects on AF associated with electrical remodeling in vivo. The ERP prolongation was notably enhanced in the RAP (about 40 ms) compared with the VNS (about 30 ms) model after NTC-801 (3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) administration, suggesting that K ACh channels play a pathophysiological role in AF associated with electrical remodeling.
The present results differ from those of other class III antiarrhythmics (I Kr blockers), of which the antiarrhythmic effects are diminished in AF with electrical remodeling. 16, 27 Constitutively active I K,ACh is increased, whereas I Kr density is decreased, leading to a triangularized and shortened action potential in the electrically remodeled atrium. 16 NTC-801 prolonged ERP independent of frequency, whereas I Kr blockers do so dependently on reverse frequency, which blunts the effects of I Kr blockers under tachyarrhythmias. Thus, AF might be more effectively treated using blockers of I K,ACh than of I Kr .
Potential Clinical Implications and Study Limitations
Considerable attention has recently focused on I K,ACh because of the involvement in atrial but not ventricular repolarization and in AF susceptibility. 6 Atrial tachypacing in dogs results in electrical remodeling with an increased density of I K,ACh that is active in atrial cells even in the absence of muscarinic agonists. 10 In addition, atrial cardiomyocytes from patients with chronic AF show constitutively active K ACh channels, 11 although patients with paroxysmal AF probably do not have constitutively active K ACh channels. 28 It is assumed that paroxysmal AF occurring at night, at rest, and/or after consuming meals or alcohol is caused at least partly by the activation of ligand-operated K ACh channels. 12 However, the contribution of K ACh channel activation to the development and maintenance of AF in patients remains unknown because a highly selective K ACh channel blocker has not been clinically available. Here, we demonstrated that NTC-801 should be a useful pharmacological tool with which to investigate the I K,ACh contribution to AF and that it shows promise as a new treatment for AF.
The most recent data demonstrated the unequal distribution of inward rectifier K ϩ currents in atria of patients with paroxysmal AF. 29 The left-to-right gradient in inward rectifier background current is suggested to contribute to the left-to-right atrium dominant frequency gradients in paroxysmal AF patients, accelerating frequency and stability of reentry-promoting rotors. The NTC-801-mediated inhibition of I K,ACh might modify not only atrial refractoriness but also AF-promoting reentrant sources in the experimental models described.
The disadvantage of attempts at rhythm control using existing antiarrhythmic drugs comprise limited efficacy and a significant risk of adverse effects, such as proarrhythmia and reduced cardiac function. 6, 7 The present study showed that a selective I K,ACh blockade with NTC-801 has little effect on membrane currents and action potentials in ventricular cells, which is reflected by the absence of QRS and QTc changes in vivo. These results indicate that a selective I K,ACh blocker is unlikely to produce adverse ventricular effects.
We do not fully understand either the pathophysiological role of I K,ACh in AF or its relevance between humans and dogs, although I K,ACh plays key roles in the human and canine atrium. As with all animal experiments, whether the efficacy of NTC-801 in dogs can be directly extrapolated to humans remains unknown. From this perspective, NTC-801 will require clinical assessment to verify the importance of K ACh channels and to ascertain the therapeutic utility of a selective I K,ACh blocker. Since the phase I study has been completed, clinical proof of concept for this compound will be clarified soon.
Conclusions
The present study demonstrated that a highly selective I K,ACh blockade with NTC-801 prolongs atrial-selective ERP, decreases AF inducibility in an AF model with electrical remodeling, and converts AF to normal sinus rhythm in vagally induced and ectopic automaticity-induced AF models. These findings suggest that I K,ACh may be important in the development and maintenance of AF. 
